万赛维医保给报销吗？

The trade name of valganciclovir hydrochloride is an antiviral drug used to treat patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis, and to prevent CMV infection in high-risk solid organ transplant patients.

The recommended dose of valcyte for the treatment of induction of cytomegalovirus retinitis is 900 mg (two 450 mg tablets) twice daily for 21 days. Maintenance: After induction therapy, or in adult patients with inactive cytomegalovirus retinitis, the recommended dose is 900 mg orally once daily. Use with caution in patients with impaired renal function; dosage needs to be adjusted under physician advice.

In May 2001, the US FDA approved the market. Valcyte is clinically used to treat acute retinitis caused by CMV infection in patients with acquired immunodeficiency syndrome. In May 2003, its indications were expanded. Valcyte is used to prevent and treat secondary CMV infection in organ transplant recipients.

In August 2006, valcyte was launched in China with a specification of 450mg*60 tablets/box and a relatively high price of $16,500/box. Due to the high price of the original drug, many patients want to know whether Vancevi can be reimbursed by medical insurance?

Unfortunately, although Valcyte has been launched in my country, Vancevir is not included in my country's medical insurance catalogue, which means that patients cannot be reimbursed by medical insurance, which is undoubtedly worse for patients with greater financial pressure. Currently, the most cost-effective product on the market is Vancevir launched in India. According to Medical Travel, Roche’s Valgancilovir (valgancilovir hydrochloride tablets, valgansiklovir) 450mg*60 tablets is priced at approximately RMB 5,500 in Indian pharmacies. Patients can go to India to purchase in person, or contact Medical Travel to purchase.